Verve Therapeutics

Verve Therapeutics is a biotechnology company focused on discovering and developing therapies that safely edit the genomes of adults to confer lifelong protection against coronary artery disease, the most common type of heart disease and the leading cause of death worldwide.


Series B




Org chart

Sekar Kathiresan
Co-Founder & CEO
J. Keith Joung
Barry Ticho
Andrew Ashe
President & COO
Andrew Bellinger
Chief Scientific Officer & Chief Medical Officer
Leslie Stolz
SVP, Regulatory Affairs
Troy Lister
SVP, Research
Julia Chapman
SVP, Corporate Strategy & Planning
Hari Jayaram
VP, Editing & Discovery
Yasser El-Gamal
VP, Legal Affairs & Chief Intellectual Property Counsel
Joe Biedenkapp
VP, Editing Development
Victoria Bartlett
VP, Program & Alliance Management
Jeffrey Meltzer
VP, Quality
Andrew Sheely
Executive Director, IT
Morgan Jones
Senior Director, Business Development & Corporate Strategy
Derek Sethachutkul
Senior Director, External Manufacturing
Joel Cooper
Senior Director, Toxicology
Seka Lazare
Associate Director, Next Generation Sequencing
Emily Cronin
Associate Director, Benefits
Caitlin Moreno
Senior Manager, Environmental, Health & Safety
Pratik Randeria
Director, Process Development
Maryam Habibian
Director, Discovery Chemistry
Christopher Manoogian
Associate Director, Laboratory, Quality Control